https://www.selleckchem.com/btk.html
The primary outcome was ICU length of stay. There was a significant decrease in ICU length of stay when comparing the year after the protocol initiation to years prior, from a median of 6.19 days to 4 days (2017 vs. 2019, 0.0001), and a median of 5.88 days to 4 days (2018 vs. 2019, 0.0001). Secondary outcomes demonstrated a significant reduction in total administered volumes of inotropic medication(milrinone). All other vasopressors demonstrated no differences across years. Hospital length of stay comparisons did not demonstrate a signific